Happy hump-day, folks, but no - the market didn't get over its key hump. It didn't even really try. Ugh. We'll look at what happened and what it means in a moment, as we always do. We want to start with the most important news first though, which is this morning's press release from Vitality Biopharma (VBIO). Just to get everybody up to speed in case you've not been able to keep up, here's the crash course on Vitality Biopharma. Cannabidiol is a non-psychotropic derivative of cannabis, which has demonstrated therapeutic effects for serious neurological conditions including rare seizure disorders, and for alleviating symptoms of multiple sclerosis. Vitality Biopharma's prodrugs -- drugs converted into their effective form after processed in the body -- could exert the same beneficial therapeutic effects, but with notable improvements like a better tasting formulation, better oral bioavailability, or a delayed release mechanism which enables patients using these medications to enjoy long-lasting, overnight relief. The advantages of Vitality Biopharma's science are simple. Namely, since cannabidiol doesn't create a psychoactive effect, Vitality's drugs allow for higher, more effective dosing. Better still, since these drugs are prodrugs and aren't activated until in the body, they allow for targeted delivery to the GI tract...yet can also selectively target other body parts, even as far away from the GI tract as the brain. Perhaps more than anything though, these drugs are orally-administered by virtue of being highly soluble, making them easy to use. Where things get interesting is that cannabidiol has actually been demonstrated as a viable alternative to opioid painkillers, which are dangerously addictive. Fast forward to today. This morning, VBIO announced it was moving forward with plans to develop a cannabis-based drug to treat narcotic bowel syndrome... opiate-induced abdominal pain, to be specific. It's a ridiculous paradox, to tell the truth. Opioid is a painkiller, but may actually induce pain. All too often the solution is a higher dose of opioid, which not only causes more pain, but increases the odds of developing an addiction. In that cannabidiol isn't addiction-inducing, it's a much smarter and safer alternative. And don't think for a minute that the need isn't there. As Vitality Biopharma CEO Robert Brooke explained in his letter to the market in September: "The incidence of heroin initiation is 19 times higher among those who report prior abuse of pain medications (talk about a "gateway" drug). Studies have shown that today about 75% to 86% of heroin users started with prescription opioid pain relievers. So the first exposure to opiates is far more likely to come not from heroin (as was overwhelmingly true in the 1960's), but rather from prescription drugs." Vitality Biopharma didn't say exactly when it expects to start or finish the development of a cannabis-based treatment for narcotic bowel syndrome. As James Brumley pointed out today with has take on the news though, it doesn't really matter. In other news, congratulations are in order for those of you who are also members of the Elite Opportunity Pro newsletter. You guys booked a 38% gain on Agios Pharmaceuticals (AGIO) today... in just ten trading days. It's quite freakish, actually. John Monroe figured out where the bottom was with outright perfection. How? I have no idea. The chart speaks for itself though. The day after he made the suggestion, AGIO perked up and never looked back. The exit was perfect too. John recommended investors get out of Agios Pharmaceuticals this morning before the bears took over. We mentioned this a few days ago but it bears repeating now... while you're waiting to make big money by playing the long-term game, you may be leaving money on the table by not playing any kind of short-term game. Don't know how? No problem - John and his crew know how, and they can pick trades for you. Clearly they know what they're doing. To the extent it matters (which isn't much), here's the daily chart of the S&P 500. Unable to pick up where they left off on Tuesday, traders let the index slide back a bit. Notice the VIX continues to test, but not break, a key rising support level. We still contend that's going to be more telling than the market's action itself. Having had a full week to think about it and watch it, I think there's only one thing we can count on here - nobody really knows what's going to happen next. You CAN see the masses leaned bullishly in the wake of the election's results, but it's easy to be bullish up to a point. It's hard to be bullish with the S&P 500 above 2194, though that's where the bullish mindset matters most. Anything bullishness between here and there, so what? With that as the backdrop, having observed the fallout since Tuesday of last week, I'll just respond with this ... this is not a time to freak out nor a time to be elated. This is certainly not a time to jump to conclusions about what the future holds based on a political policy. I know the financial media is trying to paint a different picture, but they're wrong. Most of the time, the market does the most boring though, not coming close to experiencing the worst or best suggested outcome. Stocks are going to do what stocks are going to do. The economy's going to do what the economy's going to do. Sure, politics can push and pull that, but it takes a long time for policy to trickle into the economy. Now's not the time to make long-term decisions. There will be plenty of time to do that later, if and when it's needed. Just sayin, take a deep breath, and maybe turn off the TV. It really doesn't help that much anyway. Finally, we just wanted to leave you with a look at one industry's stocks that tend to end the year very strong. It's healthcare equipment and services. Over the course of November and December, they gain an average of 6%. Even in a bearish year, they tend to finish the year strong. Take a look. (The white line is the multi-decade average, and the green line is how healthcare equipment and service stocks have fared so far in 2016.) Also notice the group extends the bullish trend into February of the next year. I don't know if these names will give us the usual bullish performance to end this year. I do know, however, the recent pullback has cleared the deck - so to speak - with a sizeable pullback through October. Just something to think about.